- The novel approach combines the promise of two transformative therapy technologies, AAV gene therapy and cytokine immunotherapy, into a single transformative modality
- It is believed to be the first-ever AAV gene therapy for cancer and the first AAV gene therapy to be made once and used for multiple indications
- Specifically designed to address the administration, efficacy and toxicity challenges associated with cytokine immunotherapies
- Siren is presenting first preclinical data for a new modality today at the ASGCT Annual Meeting
- Spin out of the Paulk Lab at UCSF
- Founder and CEO Nicole Paulk, PhD, is a world-renowned expert in AAV gene therapy
- Initial funding was led by Founders Fund and Lux Capital with participation from Innovation Endeavors, TechBio-focused ARTIS Ventures, Civilization Ventures and Savantus Ventures
SAN FRANCISCO, May 17, 2023 (GLOBE NEWSWIRE) — Siren Biotechnology, pioneers of Universal AAV Immuno-Gene Therapy, a revolutionary new treatment for cancer, was launched from the shadows today, concurrent with its first preclinical data presentation at ASGCT 26th Annual Meeting taking place May 16-20 in Los Angeles. Siren’s universal AAV immunogene therapy combines the promise of two transformative therapy technologies, AAV gene therapy and cytokine immunotherapy, into a single modality aimed at redefining how tumor cells are destroyed and anti-tumor immunity induced. The company’s name was inspired by the powerful signal that Universal AAV Immuno-Gene Therapy sends to the immune system, triggering an immediate and comprehensive anti-tumor response. shortcut Here for the press release on the ASGCT presentation and Siren’s preclinical data.
“The world needs big, bold, new ideas to fight cancer, and universal AAV immunogene therapy is just that. Our design and development of this modality is redefining both AAV gene therapy and cytokine immunotherapy, thereby changing the game for “cancer treatment,” said Nicole Paulk, PhD, Founder and CEO…
[ad_2]
Source story
